- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Elevated Levels of Circulating Endothelial Cells in Pregnancies Complicated by Pre-Eclampsia and/or Fetal Growth Restriction

# Elevated Levels of Circulating Endothelial Cells in Pregnancies Complicated by Pre-Eclampsia and/or Fetal Growth Restriction

This SMFM 2025 poster reports a RareCyte liquid-biopsy immunofluorescence assay that enumerates circulating endothelial cells (CECs) in maternal blood and finds CEC counts elevated in third-trimester pregnancies complicated by preeclampsia and/or fetal growth restriction relative to healthy pregnancies — preliminary support for CEC enumeration as a predictive biomarker of pregnancy complications.

Presented by RareCyte and Swedish Medical Center.

Read or download to see:

- A four-parameter immunofluorescence assay on the RareCyte liquid-biopsy platform identifies circulating endothelial cells from a maternal blood sample. CECs are scored as nucleated, CD45-negative cells positive for either or both endothelial markers VE-cadherin (CD144) and MCAM (CD146); blood is prepared with the AccuCyte system and imaged on CyteFinder instruments.

- In HUVEC spike-in validation, the assay identified model CECs with 99.7% sensitivity and 99.9% specificity using CD144, and 99.3% sensitivity and 100% specificity using CD146. Each figure aggregates eight slides per spike-in experiment, with negative-control cell lines confirming marker specificity.

- Across a third-trimester clinical cohort, population CEC counts rose from 1.5 per mL of blood in non-pregnant controls to 5.0 in healthy pregnancies and 11.6 in complicated pregnancies, with counts elevated in both preeclampsia and fetal growth restriction relative to healthy third-trimester pregnancies. The exploratory cohort was small — 29 third-trimester pregnancies (10 uncomplicated, 7 FGR, 4 PE, 8 PE plus FGR) and 10 non-pregnant controls — and the authors present CEC enumeration as a candidate predictive biomarker warranting further study.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/38181b42312e8912f6bb4f99b8498af06b1b9774.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/38181b42312e8912f6bb4f99b8498af06b1b9774.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Publication](https://doi.org/10.1097/pai.0000000000001311) CyteFinder Applied Immunohistochemistry & Molecular Morphology 2026
### Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score
[View Publication](https://doi.org/10.1097/pai.0000000000001311) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) CyteFinder Clinical Cancer Research 2025
### Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083604/) CyteFinder medRxiv 2025
### Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083604/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226049/) CyteFinder JCI Insight 2025
### Imlunestrant, a next-generation oral SERD, overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226049/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162492/) CyteFinder npj Breast Cancer 2024
### Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162492/) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024
### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood
[Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018817/) CyteFinder Nature Communications 2024
### Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018817/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) CyteFinder 2024
### Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) CyteFinder 2024
### Development and validation of an assay for the characterization of SSTR2 expression on CTCs from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/16a6f80f656d101bdd81726d83d0246d16619b83.pdf) CyteFinder 2024
### A Novel Method for Placental Evaluation: Isolation of Intact Circulating Trophoblast Cells from Maternal Circulation
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/16a6f80f656d101bdd81726d83d0246d16619b83.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10761880/) CyteFinder npj Breast Cancer 2024
### Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10761880/)